Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI)
Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease
Sponsor: Genentech, Inc.
A PHASE3 clinical study on Adenocarcinoma of Biliary Tract and Colon Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by Genentech, Inc. and has accumulated 11 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — Jun 2025 [monthly]
Recruiting PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE3
▶ Show 6 earlier versions
-
Sep 2024 — Jan 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE3
-
Mar 2023 — Dec 2023 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Mar 2023 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Georgetown University
- Natera, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .